Gd-BOPTA/Dimeg: experimental disease imaging.
The novel tissue-specific contrast agent, Gd-BOPTA/Dimeg, was tested in MR imaging of experimental focal liver disease and of acute myocardial ischemia in rats. Directly implanted liver tumors and blood-borne metastases were used as models for focal liver disease and occlusion of the lower anterior descending coronary artery as model for acute ischemia. The studies with implanted tumors, at a dose level of 250 mumol/kg, showed a very high (370%) and persistent (greater than 2 h) increase in the tumor-liver contrast-to-noise ratio (CNR), owing to selective enhancement of normal liver parenchyma signal intensity. While all blood-borne metastases showed a similar late CNR enhancement, some of them experienced early contrast loss due to transient signal intensity enhancement. In myocardial imaging, Gd-BOPTA/Dimeg produced a signal intensity enhancement in normal myocardium and an injured area-normal area CNR enhancement which were both much stronger and more persistent than those produced by Gd-DTPA/Dimeg.
Cavagna
F
F
Research and Development Division, Bracco Industria Chimica SpA, Milan, Italy.
Daprà
M
M
Maggioni
F
F
de Haën
C
C
Felder
E
E
D000085:Acetates; D000818:Animals; D003287:Contrast Media; D003327:Coronary Disease / Q000175:diagnosis*; D005682:Gadolinium; D019786:Gadolinium DTPA; D008114:Liver Neoplasms, Experimental / Q000175:diagnosis*; D008536:Meglumine / Q000031:analogs & derivatives*; D009942:Organometallic Compounds; D004369:Pentetic Acid; D051381:Rats; D011919:Rats, Inbred Strains
D000085:Acetates; D003287:Contrast Media; D009942:Organometallic Compounds; C064572:gadobenic acid; D008536:Meglumine; D004369:Pentetic Acid; D005682:Gadolinium; D019786:Gadolinium DTPA